Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mivelsiran in adults with early-stage Down syndrome-associated Alzheimer's disease
NL-OMON61405Phase 2Not yet recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Sep 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of mivelsiran in dementia due to Down syndrome (DS-AD), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Change from baseline to Month 24 in amyloid PET as measured in CLs. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
mivelsiran
03
Conditions
dementia due to Down syndrome (DS-AD)
Beyond the preview
Go deeper on NL-OMON61405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61405.